1. Kane, RC, Bross, PF, Farrell, AT, et al. Velcade®: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003; 8: 508–513.
Google Scholar | Crossref | Medline | ISI2. Tan, CRC, Abdul-Majeed, S, Cael, B, et al. Clinical pharmacokinetics and pharmacodynamics of bortezomib. Clin Pharmacokinet 2019; 58: 157–168.
Google Scholar | Crossref | Medline3. Li, G, Wang, S, Li, N, et al. Proteasome inhibition with bortezomib induces apoptosis of long-lived plasma cells in steroid-resistant or relapsed immune thrombocytopaenia. Thromb Haemost 2018; 118: 1752–1764.
Google Scholar | Crossref | Medline4. Neubert, K, Meister, S, Moser, K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748–755.
Google Scholar | Crossref | Medline | ISI5. Hainz, N, Thomas, S, Neubert, K, et al. The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture. Nephron Exp Nephrol 2012; 120: e47–e58.
Google Scholar | Crossref | Medline6. Ichikawa, HT, Conley, T, Muchamuel, T, et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum 2012; 64: 493–503.
Google Scholar | Crossref | Medline7. Khodadadi, L, Cheng, Q, Alexander, T, et al. Bortezomib plus continuous B cell depletion results in sustained plasma cell depletion and amelioration of lupus nephritis in NZB/W F1 mice. PLoS ONE 2015; 10: e0135081.
Google Scholar | Crossref8. Taylor, EB, Barati, MT, Powell, DW, et al. Plasma cell depletion attenuates hypertension in an experimental model of autoimmune disease. Hypertension 2018; 71: 719–728.
Google Scholar | Crossref | Medline9. Griger, Z, Tóth, BI, Baráeth, S, et al. Different effects of bortezomib on the expressions of various protein kinase C isoenzymes in T cells of patients with systemic lupus erythematosus and in Jurkat cells. Scand J Immunol 2012; 75: 243–248.
Google Scholar | Crossref | Medline10. Alexander, T, Cheng, Q, Klotsche, J, et al. Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors. Eur J Immunol 2018; 48: 1573–1579.
Google Scholar | Crossref | Medline11. Yannaki, E, Papadopoulou, A, Athanasiou, E, et al. The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats. Arthritis Rheum 2010; 62: 3277–3288.
Google Scholar | Crossref | Medline12. van der Heijden, JW, Oerlemans, R, Lems, WF, et al. The proteasome inhibitor bortezomib inhibits the release of NFκB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients. Clin Exp Rheumatol 2009; 27: 92–98.
Google Scholar | Medline13. Xiao, F, Lin, X, Tian, J, et al. Proteasome inhibition suppresses Th17 cell generation and ameliorates autoimmune development in experimental Sjögren’s syndrome. Cell Mol Immunol 2017; 14: 924–934.
Google Scholar | Crossref14. Gomez, AM, Vrolix, K, Martínez-Martínez, P, et al. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol 2011; 186: 2503–2513.
Google Scholar | Crossref | Medline | ISI15. Gomez, AM, Willcox, N, Vrolix, K, et al. Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients. J Immunol 2014; 193: 1055–1063.
Google Scholar | Crossref | Medline | ISI16. Fissolo, N, Kraus, M, Reich, M, et al. Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. Eur J Immunol 2008; 38: 2401–2411.
Google Scholar | Crossref | Medline | ISI17. Barcellini, W, Fattizzo, B. How I treat warm autoimmune hemolytic anemia. Blood 2021; 137: 1283–1294.
Google Scholar | Crossref | Medline18. Berentsen, S . How I treat cold agglutinin disease. Blood 2021; 137: 1295–1303.
Google Scholar | Crossref | Medline19. Barcellini, W, Fattizzo, B. The changing landscape of autoimmune hemolytic anemia. Front Immunol 2020; 11: 946–912.
Google Scholar | Crossref20. Jäger, U, Barcellini, W, Broome, CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting. Blood Rev 2020; 41: 100648.
Google Scholar | Crossref | Medline21. Zaninoni, A, Giannotta, JA, Gallì, A, et al. The immunomodulatory effect and clinical efficacy of daratumumab in a patient with cold agglutinin disease. Front Immunol 2021; 12: 649441.
Google Scholar | Crossref | Medline22. Ratnasingam, S, Walker, PA, Tran, H, et al. Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. Blood Adv 2016; 1: 31–35.
Google Scholar | Crossref | Medline23. Carson, KR, Beckwith, LG, Mehta, J. Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood 2010; 115: 915.
Google Scholar | Crossref | Medline24. Danchaivijitr, P, Yared, J, Rapoport, A. Successful treatment of IgG and complement-mediated autoimmune hemolytic anemia with bortezomib and low-dose cyclophosphamide. Am J Hematol 2011; 86: 331–332.
Google Scholar | Crossref | Medline25. Rovira, J, Cid, J, Gutiérrez-García, G, et al. Fatal immune hemolytic anemia following allogeneic stem cell transplantation: report of 2 cases and review of literature. Transfus Med Rev 2013; 27: 166–170.
Google Scholar | Crossref | Medline26. Khandelwal, P, Davies, SM, Grimley, MS, et al. Bortezomib for refractory autoimmunity in pediatrics. Biol Blood Marrow Transplant 2014; 20: 1641–1665.
Google Scholar | Crossref | Medline27. Mehta, B, Mahadeo, K, Zaw, R, et al. Bortezomib for effective treatment of a child with refractory autoimmune hemolytic anemia post allogeneic hematopoietic stem cell transplant. Pediatr Blood Cancer 2014; 61: 2324–2325.
Google Scholar | Crossref | Medline28. Waespe, N, Zeilhofer, U, Güngör, T. Treatment-refractory multi-lineage autoimmune cytopenia after unrelated cord blood transplantation: remission after combined bortezomib and vincristine treatment. Pediatr Blood Cancer 2014; 61: 2112–2114.
Google Scholar | Crossref | Medline29. Hosoba, S, Jaye, DL, Cohen, C, et al. Successful treatment of severe immune hemolytic anemia after allogeneic stem cell transplantation with bortezomib: report of a case and review of literature. Transfusion 2015; 55: 259–264.
Google Scholar | Crossref | Medline30. Wang, Y, Zhou, W, Zhang, Z. Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient. Rheumatology 2015; 54: 194–195.
Google Scholar | Crossref | Medline | ISI31. Rossi, G, Gramegna, D, Paoloni, F, et al. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. Blood 2018; 132: 547–550.
Google Scholar | Crossref | Medline32. Liu, XH, Liu, MX, Jin, F, et al. Concomitant cryoglobulinemic vasculitis and cold agglutinin disease successfully treated with bortezomib; A case report. Medicine 2019; 98: e14201.
Google Scholar33. Sefland, Ø, Randen, U, Berentsen, S. Development of multiple myeloma of the IgA type in a patient with cold agglutinin disease: transformation or coincidence? Case Rep Hematol 2019; 2019: 1610632.
Google Scholar | Medline34. Ames, PRJ, Jeffrey, S. Bortezomib and rituximab in multiply relapsed primary warm autoimmune hemolytic anemia. Ann Hematol 2021; 100: 2415–2416.
Google Scholar | Crossref | Medline35. Fadlallah, J, Michel, M, Crickx, E, et al. Bortezomib and dexamethasone, an original approach for treating multi-refractory warm autoimmune haemolytic anaemia. Br J Haematol 2019; 187: 124–128.
Google Scholar | Crossref | Medline36. Knops, N, Emonds, MP, Herman, J, et al. Bortezomib for autoimmune hemolytic anemia after intestinal transplantation. Pediatr Transplant 2020; 24: e13700.
Google Scholar | Crossref | Medline37. Trivedi, HL, Terasaki, PI, Feroz, A, et al. Abrogation of Anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555–1561.
Google Scholar | Crossref | Medline | ISI38. Shortt, J, Oh, DH, Opat, SS. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med 2013; 368: 90–92.
Google Scholar | Crossref | Medline | ISI39. Yates, S, Matevosyan, K, Rutherford, C, et al. Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report. Transfusion 2014; 54: 2064–2067.
Google Scholar | Crossref | Medline40. Mazepa, M, Raval, JS, Moll, S, et al. Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol 2014; 164: 900–902.
Google Scholar | Crossref | Medline | ISI41. van Balen, T, Schreuder, MF, de Jong, H, et al. Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib. Eur J Haematol 2014; 92: 80–82.
Google Scholar | Crossref | Medline42. Patel, PP, Becker, J, Freyer, C, et al. Rituximab-refractory thrombotic thrombocytopenic purpura responsive to intravenous but not subcutaneous bortezomib. Transfusion 2016; 56: 970–974.
Google Scholar | Crossref | Medline43. Acedillo, R, Govind, M, Kashgary, A, et al. Treatment of severe, refractory and rapidly evolving thrombotic thrombocytopenic purpura. BMJ Case Rep 2016; 2016: bcr2016215491.
Google Scholar | Medline44. Patriquin, CJ, Thomas, MR, Dutt, T, et al. Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura. Br J Haematol 2016; 173: 779–785.
Google Scholar | Crossref | Medline45. Pandey, MR, Vachhani, P, Ontiveros, EP. Remission of severe, relapsed, and refractory TTP after multiple cycles of bortezomib. Case Rep Hematol 2017; 2017: 9681832.
Google Scholar | Medline46. Sun, R, Gu, W, Ma, Y, et al. Relapsed/refractory acquired thrombotic thrombocytopenic purpura in a patient with Sjögren syndrome. Medicine 2018; 97: e12989.
Google Scholar | Crossref47. Lancelot, M, Miller, MJ, Roback, J, et al. Refractory thrombotic thrombocytopenic purpura related to checkpoint inhibitor immunotherapy. Transfusion 2021; 61: 322–328.
Google Scholar | Crossref | Medline48. Tkachenko, O, Lapin, S, Maslyansky, A, et al. Relapsing Evans syndrome and systemic lupus erythematosus with antiphospholipid syndrome treated with Bortezomib in combination with plasma exchange. Clin Immunol 2019; 199: 44.
Google Scholar | Crossref | Medline49. Fröhlich, K, Holle, JU, Aries, PM, et al. Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma. Ann Rheum Dis 2011; 70: 1344–1345.
Google Scholar | Crossref |